FY2024 Earnings Estimate for Humana Inc. Issued By Cantor Fitzgerald (NYSE:HUM)

Humana Inc. (NYSE:HUM) – Analysts at Cantor Fitzgerald decreased their FY2024 earnings estimates for Humana in a research note issued to investors on Thursday, April 25th. Cantor Fitzgerald analyst S. James now forecasts that the insurance provider will earn $16.04 per share for the year, down from their previous estimate of $16.07. Cantor Fitzgerald has a “Neutral” rating and a $360.00 price objective on the stock. The consensus estimate for Humana’s current full-year earnings is $16.06 per share.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter last year, the business posted $9.38 EPS. The firm’s revenue was up 10.7% compared to the same quarter last year.

A number of other research analysts have also weighed in on the stock. Barclays cut their price target on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 2nd. Bank of America reissued a “neutral” rating and issued a $342.00 price target (down previously from $470.00) on shares of Humana in a research note on Tuesday, April 2nd. Oppenheimer decreased their price objective on Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a report on Thursday. Wells Fargo & Company reduced their price target on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research report on Monday, April 8th. Finally, Mizuho cut their price objective on shares of Humana from $550.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, January 26th. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $433.74.

Humana Trading Down 1.8 %

NYSE:HUM opened at $305.91 on Friday. The business’s 50-day simple moving average is $327.77 and its 200-day simple moving average is $394.49. Humana has a fifty-two week low of $299.23 and a fifty-two week high of $541.21. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.59. The stock has a market capitalization of $36.91 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 1.85 and a beta of 0.45.

Institutional Investors Weigh In On Humana

Hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley boosted its stake in shares of Humana by 6.2% in the third quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock valued at $992,938,000 after buying an additional 119,760 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Humana by 35.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock worth $741,409,000 after purchasing an additional 402,559 shares in the last quarter. Norges Bank bought a new position in shares of Humana in the fourth quarter worth $676,800,000. Northern Trust Corp lifted its position in Humana by 5.1% during the third quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock worth $645,850,000 after purchasing an additional 64,245 shares during the period. Finally, Sanders Capital LLC acquired a new stake in Humana during the fourth quarter worth about $489,300,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Buying and Selling at Humana

In related news, Director Jorge S. Mesquita acquired 545 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was purchased at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the transaction, the director now directly owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio is 22.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.